Healthy Participants
Conditions
Keywords
Healthy participants, Pharmacodynamic, Pharmacokinetics, Intravenous Endotoxin-Induced Model, Acute Inflammation, JNJ-26528398, Anti-inflammatory
Brief summary
The purpose of this study is to evaluate the anti-inflammatory properties of JNJ-26528398 using an intravenous (IV) endotoxin-induced model of acute, transient inflammation.
Detailed description
This is a 2-part, single center, double-blind study (neither physician nor participant knows the treatment that the participant receives). Part 1 is designed to evaluate the safety, tolerability, and pharmacokinetics (level of drug in the blood) of a dosing regimen of an investigational drug (JNJ-26528398) prior to its use in Part 2. In Part 1, participants will be assigned by chance to receive either 3 mg/day JNJ-26528398 (6 participants) or placebo (3 participants) for 7 consecutive days while staying in the clinic for 10 days. Placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect. Part 2 is designed to evaluate the anti-inflammatory properties of JNJ-26528398 by measuring markers of inflammation in the blood after intravenous (IV) administration of a substance (endotoxin) which activates the immune system and temporarily causes flu-like symptoms. In Part 2, participants will be assigned by chance to receive up to 3 mg/day JNJ-26528398 (6 participants) or placebo (4 participants) for up to 7 consecutive days while staying in the clinic for 10 days. Endotoxin will be given on the last day of study drug administration. Participants will remain in bed for at least 6 hours after endotoxin administration and will be closely monitored by study personnel.
Interventions
DRUGJNJ-26528398
In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
DRUGPlacebo
In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Nonsmoker * Be in good health on the basis of physical examination, medical history, and electrocardiogram (ECG) * Must have good exercise tolerance * Have a body mass index of 18-29 kg/m2, inclusive, and body weight between 60 and 85 kg, inclusive * Have a history of consistent dental hygiene and dental care * Must adhere to required contraception (subject and partner, if applicable) during the study and for 3 months after study * Must agree to not donate sperm during the study and for 3 months after study
Exclusion criteria
* Is currently enrolled in an investigational study, has recently received an investigational drug (including investigational vaccines), or has donated blood within 3 months * Has had a vaccination within past 3 months * Has history of significant drug or alcohol abuse within past 2 years or has a positive drug screen * Blood donation within past 3 months * Part 2 only: Has received endotoxin within past 3 months, or has a known allergy or history of significant adverse reaction to endotoxin or its excipients lactose and polyethylene glycol 6000
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The TNF-α concentrations in plasma (Part 2) | Days 7-8 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Other markers of inflammation in blood (Part 2) | Days 7-8 | — |
| Profile of Mood States (POMS) (Part 2) | Days 1 and 7 | The POMS Standard Form contains 65 items and assesses six dimensions of mood: tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. Each item is rated by the participant using a 5-point scale ranging from 1 (not at all) to 5 (extremely). |
| Incidence of adverse events amongst participants (Parts 1 and 2) | Days -1 to 10 and Day 24 | — |
| Area under the curve (AUC) of JNJ-26528398 (Parts 1 and 2) | Days 1-10 | Blood concentrations sampled at frequent intervals |
| Maximum plasma concentration (Cmax) of JNJ-26528398 (Parts 1 and 2) | Days 1-10 | — |
Countries
Belgium
Outcome results
None listed